William Blair Has Bearish Forecast for GPCR Q3 Earnings

Key Points

• William Blair downgraded its Q3 2025 earnings estimates for Structure Therapeutics, expecting a loss of ($0.36) per share, down from a previous estimate of ($0.27).
• The company reported ($0.36) earnings per share for the recent quarter, which was below the analysts' consensus estimate of ($0.28).
• Structure Therapeutics is currently rated as a "Buy" by eight investment analysts, with an average target price of $75.71, despite recent price target cuts from several firms.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) - Analysts at William Blair cut their Q3 2025 earnings estimates for Structure Therapeutics in a note issued to investors on Wednesday, August 6th. William Blair analyst A. Hsieh now expects that the company will post earnings of ($0.36) per share for the quarter, down from their previous forecast of ($0.27). The consensus estimate for Structure Therapeutics' current full-year earnings is ($0.82) per share. William Blair also issued estimates for Structure Therapeutics' Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.35) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.51) EPS and FY2027 earnings at ($1.51) EPS.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08).

GPCR has been the topic of a number of other reports. Guggenheim cut their target price on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a research note on Thursday. HC Wainwright dropped their price objective on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a research report on Thursday. Citigroup started coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 price objective on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 target price on shares of Structure Therapeutics in a research note on Monday, June 23rd. Finally, JMP Securities dropped their target price on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a report on Thursday. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $75.71.

Structure Therapeutics Price Performance

GPCR stock opened at $16.31 on Monday. Structure Therapeutics has a 1 year low of $13.22 and a 1 year high of $45.37. The firm has a market capitalization of $939.46 million, a P/E ratio of -15.53 and a beta of -1.89. The business's 50-day moving average is $19.78 and its two-hundred day moving average is $21.76.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Deep Track Capital LP grew its holdings in shares of Structure Therapeutics by 129.4% during the fourth quarter. Deep Track Capital LP now owns 2,800,000 shares of the company's stock worth $75,936,000 after purchasing an additional 1,579,492 shares during the last quarter. Vestal Point Capital LP boosted its position in shares of Structure Therapeutics by 50.0% in the 4th quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company's stock valued at $46,782,000 after purchasing an additional 575,000 shares during the period. Boxer Capital Management LLC acquired a new stake in shares of Structure Therapeutics in the 4th quarter valued at about $13,560,000. Pacific Heights Asset Management LLC purchased a new position in Structure Therapeutics during the 2nd quarter worth approximately $9,540,000. Finally, Marshall Wace LLP increased its position in Structure Therapeutics by 339.6% during the fourth quarter. Marshall Wace LLP now owns 583,207 shares of the company's stock worth $15,817,000 after buying an additional 450,531 shares during the period. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.